leisure time -WSS

leisure time

author：explore 2025-10-01 10:37:58 - browse：87

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： It's been 20 years since Dolly the sheep. Where's my clone?

focus

WSS

Behind warning on Apellis’s eye drug lies a conflict of interest

Public health communication lessons from Covid

What Congress can do to address the rural doctor shortage

Experts study whether long Covid risk adds up with each reinfection

CommonSpirit Health keeps growing, even as it loses money

Emergency workers more likely to restrain Black patients: study

hotspot

leisure time

entertainment

Jerome Adams on the need for new antivirals for Covid

CDC: Cases of alpha

In Memoriam: Notable people who died in 2023

Readout LOUD podcast: possible new ALS drug, artificial wombs

BioMarin wins approval for gene therapy to treat hemophilia A

Microbiome research is starting to find links to chronic diseases

Medicare proposal to cover medical devices draws a mixed reaction

Alexander Hamilton and the argument for universal insurance

Medical leaders decry Supreme Court decision on affirmative action

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

focus

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Public health communication lessons from Covid

Emergency workers more likely to restrain Black patients: study

Medical student insurance fails on mental health care coverage

Behind warning on Apellis’s eye drug lies a conflict of interest

focus

leisure time

focus

leisure time